Besides bold letters to world leaders, Trump is working on a subtler tariff strategy

President Trump's tariff strategy encompasses two distinct approaches: the high-profile, country-specific IEEPA tariffs and a less visible but legally more robust application under Section 232 of the 1962 trade law, exemplified by his stated intent to levy tariffs on pharmaceuticals. While IEEPA tariffs target approximately 70% of imports and face ongoing legal challenges, Section 232 tariffs, covering about 30% of imports, are justified by national security and have largely withstood court scrutiny. This indicates a significant and potentially expanding component of his trade policy, offering a more durable mechanism for imposing tariffs across specific sectors and potentially impacting global supply chains.

Analysis

The U.S. administration's trade policy operates on a dual-track system, combining broad, legally contentious tariffs under the International Emergency Economic Powers Act (IEEPA) with a more targeted and legally durable strategy using Section 232 of the 1962 trade law. While the IEEPA tariffs are more sweeping, covering an estimated 70% of imports, they face significant legal headwinds, having been ruled illegal by a federal court pending appeal. In contrast, Section 232 tariffs, justified on national security grounds, cover roughly 30% of imports and have successfully withstood multiple court challenges. The administration's stated intent to impose new tariffs on pharmaceuticals exemplifies this latter approach, with a plan to start with low rates and escalate them significantly over a year to incentivize domestic production. This highlights a strategic pivot towards using a legally resilient mechanism to target specific industries. However, experts cited in the article question the policy's efficacy, noting that tariffs on inputs like steel and aluminum can raise costs for other critical sectors such as aerospace and that alienating allies could undermine broader geopolitical objectives like de-risking from China.

Key Decisions for Investors

• Investors should immediately assess exposure within the pharmaceutical sector, as it is explicitly named as the next target for legally robust Section 232 tariffs, which could disrupt supply chains and impact profitability.
• It is crucial to differentiate between the two tariff types when evaluating risk: the broad IEEPA tariffs carry significant legal uncertainty and could be reversed, while the industry-specific Section 232 tariffs represent a more durable and predictable policy risk.
• Portfolio managers should screen for companies with high dependency on imported raw materials or finished goods, as the administration's 'revolutionary' and legally upheld use of Section 232 signals a persistent risk of tariffs expanding to other sectors deemed vital to national security.
• Consider the second-order effects of this trade strategy, as tariffs on foundational materials like steel and aluminum are noted to increase costs for downstream industries, potentially compressing margins for manufacturers in sectors like aerospace and heavy machinery.